Anixa Biosciences, Inc.
$2.77
$0.01 (+0.36%)
$2.69Day Range$2.79
Key Statistics
Market Cap
$95.95M
Shares Outstanding
34.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 7, 1983
Round Lot
100
Locale
US
Trading Data
Day Open
$2.78
Day High
$2.79
Day Low
$2.69
Volume
315.2K
VWAP
$2.75
Prev Close
$2.76
Transactions
--
Acc. Volume
--
About Anixa Biosciences, Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
PHARMACEUTICAL PREPARATIONSSIC 28344 employees3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118408-708-9808IPO Oct 7, 1983US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000715446
- Composite FIGI
- BBG000BG3J79
- Share Class FIGI
- BBG001S5Q1P7
- Ticker Root
- ANIX
- SIC Code
- 2834
About Anixa Biosciences, Inc. (ANIX) Stock
Anixa Biosciences, Inc. (ANIX) closed the 2026-09-18 session at $2.77, up 0.36% versus the previous close (+0.01). The stock opened at $2.78 and traded between $2.69 and $2.79 during that session. Session trading volume was 315K shares. The volume-weighted average price (VWAP) is $2.75.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Anixa Biosciences, Inc. has a market capitalization of $95.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ANIX is listed on the XNAS exchange. The company employs approximately 4 people. Anixa Biosciences, Inc. is headquartered in SAN JOSE, CA. The recorded listing date is 1983-10-07.
On this page you can find market ANIX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.